Accuray (ARAY) Reports Q4 Results; Guides Q1, FY12
Accuray Incorporated (NASDAQ: ARAY) reported Q4 EPS of ($0.40), which may not compare to the analyst estimate of $0.07 (includes costs related to TomoTherapy deal). Revenue for the quarter came in at $75.2 million versus the consensus estimate of $64.83 million.
Sees Q1 2012 revenue of $80-$85 million, versus the consensus of $93.33 million.
Sees FY2012 revenue of $400-$415 million, versus the consensus of $377.67 million.
Sees Q1 2012 revenue of $80-$85 million, versus the consensus of $93.33 million.
Sees FY2012 revenue of $400-$415 million, versus the consensus of $377.67 million.